Mov­ing past a pa­tient death, Po­sei­da of­fers an ear­ly snap­shot of proof of ef­fi­ca­cy for a next-gen sol­id tu­mor CAR-T

Ten months af­ter the FDA took the shack­les off Po­sei­da’s study for a CAR-T di­rect­ed against cas­trate-re­sis­tant prostate can­cer, the ex­ec­u­tive team is now rolling out an ear­ly snap­shot of the proof-of-con­cept da­ta it’s look­ing for in a small, ear­ly-stage study.

Test­ed in 9 heav­i­ly pre-treat­ed pa­tients — with an av­er­age of 6 pri­or ther­a­pies — in­ves­ti­ga­tors tracked a sig­nif­i­cant, 50%-plus drop in PSA lev­els in 3 of those pa­tients and what they called a “con­cor­dant” imag­ing re­sult for tu­mor ef­fect. One pa­tient had a com­plete re­sponse — the ide­al re­sult for any can­cer study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER